Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems. / Tran, Thuy; Siqueira, Scheyla D V S; Amenitsch, Heinz; Rades, Thomas; Müllertz, Anette.

In: European Journal of Pharmaceutical Sciences, Vol. 108, 15.10.2017, p. 62-70.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Tran, T, Siqueira, SDVS, Amenitsch, H, Rades, T & Müllertz, A 2017, 'Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems', European Journal of Pharmaceutical Sciences, vol. 108, pp. 62-70. https://doi.org/10.1016/j.ejps.2016.11.022

APA

Tran, T., Siqueira, S. D. V. S., Amenitsch, H., Rades, T., & Müllertz, A. (2017). Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems. European Journal of Pharmaceutical Sciences, 108, 62-70. https://doi.org/10.1016/j.ejps.2016.11.022

Vancouver

Tran T, Siqueira SDVS, Amenitsch H, Rades T, Müllertz A. Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems. European Journal of Pharmaceutical Sciences. 2017 Oct 15;108:62-70. https://doi.org/10.1016/j.ejps.2016.11.022

Author

Tran, Thuy ; Siqueira, Scheyla D V S ; Amenitsch, Heinz ; Rades, Thomas ; Müllertz, Anette. / Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems. In: European Journal of Pharmaceutical Sciences. 2017 ; Vol. 108. pp. 62-70.

Bibtex

@article{0501cf7c45564a0390b3da77edce33a6,
title = "Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems",
abstract = "The colloidal structures formed during lipolysis of self-emulsifying drug delivery systems (SEDDS) might affect the solubilisation and possibly the absorption of drugs. The aim of the current study is to elucidate the structures formed during the in vitro lipolysis of four SEDDS containing medium-chain glycerides and caprylocaproyl polyoxyl-8 glycerides (Labrasol), with or without monoacyl phosphatidylcholine (MAPC). In situ synchrotron small-angle X-ray scattering (SAXS) was combined with ex situ cryogenic transmission electron microscopy (cryo-TEM) and dynamic light scattering (DLS) to elucidate the generated structures. The SAXS scattering curves obtained during the lipolysis of MAPC-free SEDDS containing 43-60% w/w Labrasol displayed a lamellar phase peak at q=2.13nm(-1) that increased with Labrasol concentration, suggesting the presence of multilamellar structures (MLS) with a d-spacing of 2.95nm. However, SEDDS containing 20-30% w/w MAPC did not form MLS during the lipolysis. The cryo-TEM and DLS studies showed that MAPC-free SEDDS formed coarse emulsions while MAPC-containing SEDDS formed nanoemulsions during the dispersion in digestion medium. From the first minute and during the entire lipolysis process, SEDDS both with and without MAPC generated uni-, bi-, and oligo-lamellar vesicles. The lipolysis kinetics in the first minutes of the four SEDDS correlated with an increased intensity of the SAXS curves and the rapid transformation from lipid droplets to vesicles observed by cryo-TEM. In conclusion, the study elucidates the structures formed during in vitro lipolysis of SEDDS and the inhibitory effect of MAPC on the formation of MLS.",
author = "Thuy Tran and Siqueira, {Scheyla D V S} and Heinz Amenitsch and Thomas Rades and Anette M{\"u}llertz",
note = "Copyright {\^A}{\textcopyright} 2016. Published by Elsevier B.V.",
year = "2017",
month = oct,
day = "15",
doi = "10.1016/j.ejps.2016.11.022",
language = "English",
volume = "108",
pages = "62--70",
journal = "Norvegica Pharmaceutica Acta",
issn = "0928-0987",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Monoacyl phosphatidylcholine inhibits the formation of lipid multilamellar structures during in vitro lipolysis of self-emulsifying drug delivery systems

AU - Tran, Thuy

AU - Siqueira, Scheyla D V S

AU - Amenitsch, Heinz

AU - Rades, Thomas

AU - Müllertz, Anette

N1 - Copyright © 2016. Published by Elsevier B.V.

PY - 2017/10/15

Y1 - 2017/10/15

N2 - The colloidal structures formed during lipolysis of self-emulsifying drug delivery systems (SEDDS) might affect the solubilisation and possibly the absorption of drugs. The aim of the current study is to elucidate the structures formed during the in vitro lipolysis of four SEDDS containing medium-chain glycerides and caprylocaproyl polyoxyl-8 glycerides (Labrasol), with or without monoacyl phosphatidylcholine (MAPC). In situ synchrotron small-angle X-ray scattering (SAXS) was combined with ex situ cryogenic transmission electron microscopy (cryo-TEM) and dynamic light scattering (DLS) to elucidate the generated structures. The SAXS scattering curves obtained during the lipolysis of MAPC-free SEDDS containing 43-60% w/w Labrasol displayed a lamellar phase peak at q=2.13nm(-1) that increased with Labrasol concentration, suggesting the presence of multilamellar structures (MLS) with a d-spacing of 2.95nm. However, SEDDS containing 20-30% w/w MAPC did not form MLS during the lipolysis. The cryo-TEM and DLS studies showed that MAPC-free SEDDS formed coarse emulsions while MAPC-containing SEDDS formed nanoemulsions during the dispersion in digestion medium. From the first minute and during the entire lipolysis process, SEDDS both with and without MAPC generated uni-, bi-, and oligo-lamellar vesicles. The lipolysis kinetics in the first minutes of the four SEDDS correlated with an increased intensity of the SAXS curves and the rapid transformation from lipid droplets to vesicles observed by cryo-TEM. In conclusion, the study elucidates the structures formed during in vitro lipolysis of SEDDS and the inhibitory effect of MAPC on the formation of MLS.

AB - The colloidal structures formed during lipolysis of self-emulsifying drug delivery systems (SEDDS) might affect the solubilisation and possibly the absorption of drugs. The aim of the current study is to elucidate the structures formed during the in vitro lipolysis of four SEDDS containing medium-chain glycerides and caprylocaproyl polyoxyl-8 glycerides (Labrasol), with or without monoacyl phosphatidylcholine (MAPC). In situ synchrotron small-angle X-ray scattering (SAXS) was combined with ex situ cryogenic transmission electron microscopy (cryo-TEM) and dynamic light scattering (DLS) to elucidate the generated structures. The SAXS scattering curves obtained during the lipolysis of MAPC-free SEDDS containing 43-60% w/w Labrasol displayed a lamellar phase peak at q=2.13nm(-1) that increased with Labrasol concentration, suggesting the presence of multilamellar structures (MLS) with a d-spacing of 2.95nm. However, SEDDS containing 20-30% w/w MAPC did not form MLS during the lipolysis. The cryo-TEM and DLS studies showed that MAPC-free SEDDS formed coarse emulsions while MAPC-containing SEDDS formed nanoemulsions during the dispersion in digestion medium. From the first minute and during the entire lipolysis process, SEDDS both with and without MAPC generated uni-, bi-, and oligo-lamellar vesicles. The lipolysis kinetics in the first minutes of the four SEDDS correlated with an increased intensity of the SAXS curves and the rapid transformation from lipid droplets to vesicles observed by cryo-TEM. In conclusion, the study elucidates the structures formed during in vitro lipolysis of SEDDS and the inhibitory effect of MAPC on the formation of MLS.

U2 - 10.1016/j.ejps.2016.11.022

DO - 10.1016/j.ejps.2016.11.022

M3 - Journal article

C2 - 27890596

VL - 108

SP - 62

EP - 70

JO - Norvegica Pharmaceutica Acta

JF - Norvegica Pharmaceutica Acta

SN - 0928-0987

ER -

ID: 169379862